ArticleTranslational cancer research2026
Survival benefit of adjuvant radiotherapy for gallbladder cancer patients with stage IIIA: a population based, propensity score-matched study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal adjuvant treatment for advanced gallbladder cancer (GBC) remains controversial. This study aimed to evaluate whether adjuvant radiotherapy (ART) after surgery confers a survival benefit in patients with advanced GBC, particularly focusing on stage IIIA disease. Methods: We retrospectively analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database (January 2010-December 2015). Patients were divided into ART and non-ART groups. Overall survival (OS) and cancer-specific survival (CSS) were evaluated using Cox proportional hazards models and Kaplan-Meier curves, with 95% confidence intervals (CIs). Propensity score matching (PSM) was applied to minimize baseline confounding. Results: A total of 2,012 eligible patients were included: 430 (21.4%) received ART, while 1,582 (78.6%) did not. After PSM, 376 matched pairs were analyzed. ART was associated with significantly improved OS [hazard ratio (HR) =0.75, 95% CI: 0.64-0.89, P<0.001] and CSS (HR =0.73, 95% CI: 0.60-0.87, P<0.001). In Subgroup Analysis, ART conferred a significant survival benefit specifically in patients with stage IIIA GBC [OS (HR =0.56, 95% CI: 0.41-0.77, P<0.001) and CSS (HR =0.54, 95% CI: 0.37-0.75, P<0.001)], whereas no significant benefit was observed for stages IIIB, IVA, or IVB. Conclusions: Our findings from this large, population-based cohort suggest that ART, may improve survival in patients with stage IIIA GBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.